People: A.P. Pharma, Inc. (APPA.O)
APPA.O on Consolidated Issue listed on NASDAQ Capital Market
1.65USD
11:10am EST
1.65USD
11:10am EST
Price Change (% chg)
$0.00 (+0.01%)
$0.00 (+0.01%)
Prev Close
$1.65
$1.65
Open
$1.69
$1.69
Day's High
$1.69
$1.69
Day's Low
$1.65
$1.65
Volume
62,492
62,492
Avg. Vol
381,111
381,111
52-wk High
$1.85
$1.85
52-wk Low
$0.38
$0.38
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Goddard, Paul | 59 | 2000 | Chairman of the Board |
| Prentki, Ronald | 51 | 2008 | President, Chief Executive Officer, Director |
| Whelan, John | 47 | 2009 | Chief Financial Officer, Vice President - Finance |
| Barr, John | 49 | 2007 | Senior Vice President - Research & Development |
| Rosenblatt, Toby | 70 | 1983 | Director |
| Turnbull, Gregory | 71 | 2009 | Director |
| Zerbe, Robert | 58 | 2002 | Director |
| Tang, Kevin | 42 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
| Goddard, Paul | Paul Goddard, Ph.D., has served as Chairman of board of Directors of A.P. Pharma, Inc. since November 2000. Dr. Goddard has served as Chief Executive Officer for ARYx Therapeutics, Inc. since 2005 and Chairman of the Board since 2003. He has also been a director of Adolor, Inc. since 2000 and of Onyx Pharmaceuticals, Inc. since 1997. From 1998 to 2000, Dr. Goddard was President and Chief Executive Officer of Elan Corporation, plc’s pharmaceutical division. From 1991 to 1998, Dr. Goddard served as Chairman and Chief Executive Officer of Neurex Corporation. In 1998, Neurex was acquired by Elan. Prior to Neurex, Dr. Goddard held various senior management positions at SmithKline Beecham. |
| Prentki, Ronald | Ronald J. Prentki has been appointed as President, Chief Executive Officer and a member of the board of Director of A.P. Pharma Inc. effective July 7, 2008. Having spent thirty years in the pharmaceutical and biotech industries, Ron Prentki joins A.P. Pharma from Easton Healthcare Ventures, LLC, a business development and consulting company he founded in 2005. Previously, he served for seven years as president and on the board of directors at Progenics Pharmaceuticals, Inc., a biopharmaceutical company focusing on the development of products for HIV, cancer and supportive care. While at Progenics, he played a role in the acquisition and development of the company's lead supportive care product RELISTOR(TM) (methylnaltrexone), which recently received FDA approval for the treatment of opioid-induced constipation in patients with advanced illness. Prior to joining Progenics, Mr. Prentki acquired significant pharmaceutical industry experience while serving as vice president of business development and strategic planning for the U.S. division of Hoffman-La Roche; vice president of business development for Sanofi Pharma & Sterling Drug; director of cardiovascular products and manager of anticancer products for Bristol-Myers Squibb; and in various management positions at Miles Laboratories. He earned his MBA at the University of Detroit, and holds an undergraduate degree in Microbiology and Public Health from Michigan State University. |
| Whelan, John | John Whelan is Chief Financial Officer and Vice President - Finance of A.P. Pharma, Inc since February 2009. He was Chief Operating Officer and Chief Financial Officer at Raven biotechnologies, inc., a private company developing antibody-based cancer therapeutics, from April 2002 until the company’s acquisition in July 2008. From January 2000 to March 2002 he was Vice President and Chief Financial Officer at Eos Biotechnology, Inc., a private therapeutic antibodies company. Prior to that, Mr. Whelan held a number of ascending management positions at Hewlett Packard Company, culminating in his tenure as Director of Corporate Development. Mr. Whelan has a BS in Engineering from the University of California, Berkeley and an MBA from the Anderson Graduate School of Management at UCLA. |
| Barr, John | John Barr, Ph.D. has served as Senior Vice President of Research and Development since September 2007, having previously served as Vice President, Research and Development since August 2000. He joined the company in 1997 as Director of Pharmaceutical Sciences. Dr. Barr has played a key role in evaluating and developing the potential of novel delivery systems. Prior to joiningthe company, he served as the Director of Biopharmaceutics for Cortech, Inc. a Denver-based biotech firm focused on the development of novel anti-inflammatory agents. In that capacity, he was involved with both the research and development aspects of the company’s intravenous and oral programs. Dr. Barr received his Ph.D. in pharmacology from the University of Glasgow in Scotland, after which he pursued post-doctoral studies at the University of Arizona. |
| Rosenblatt, Toby | Toby Rosenblatt has served as a member of the board of Directors of A.P. Pharma, Inc. since September 1983. Mr. Rosenblatt has served as President of Founders Investments, Ltd., a private investment limited partnership since 1999. Mr. Rosenblatt also serves as a director of the BlackRock Equity Liquidity Mutual Funds, Forward Management, LLC and is a trustee of numerous civic and educational institutions. |
| Turnbull, Gregory | Gregory Turnbull has served as Director of A.P. Pharma, Inc effective from February 23, 2009. He was workec Interim Chief Financial Officer and Director of the Company. He was President and Chief Executive Officer since October 2006. Mr. Turnbull has been a private investor and business consultant for over five years. Previously, he was a general partner of Cable & Howse Ventures, a venture capital firm, and also served as an investment banker with Morgan Stanley & Co. and White, Weld & Co. Mr. Turnbull also serves as Chairman of the Board for Planar Systems, Inc. and as a director of certain privately-held companies. |
| Zerbe, Robert | Robert Zerbe, M.D. has served as a member of the board of Director of A.P. Pharma, Inc. since December 2002. Dr. Zerbe has served as the Chief Executive Officer and founder of QuatRx Pharmaceuticals Company, a private biopharmaceutical company since 2000. Until 2000, Dr. Zerbe was employed by Pfizer as the Senior Vice President of Global Research and Development and Director of Development Operations. From 1993 to 2000, Dr. Zerbe served at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert as Senior Vice President worldwide, clinical research and development. Dr. Zerbe serves as a director of Anesiva, Inc. and Aastrom Biosciences, Inc. |
| Tang, Kevin | Kevin C. Tang is Director of A.P. Pharma, Inc. He is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Tang Capital Management holds a significant ownership position in A.P. Pharma’s common stock. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex. Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. He currently serves as a director of Ardea Biosciences, Inc., a publicly traded life sciences company and two private companies, RadPharm, Inc., and Prospect Therapeutics, Inc. Mr. Tang received a BS degree from Duke University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Goddard, Paul | -- |
| Prentki, Ronald | 398,591 |
| Whelan, John | -- |
| Barr, John | 435,441 |
| Rosenblatt, Toby | -- |
| Turnbull, Gregory | 636,464 |
| Zerbe, Robert | -- |
| Tang, Kevin | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Goddard, Paul | 0 | 0 |
| Prentki, Ronald | 0 | 0 |
| Whelan, John | 0 | 0 |
| Barr, John | 180,000 | 4,575 |
| Rosenblatt, Toby | 0 | 0 |
| Turnbull, Gregory | 0 | 0 |
| Zerbe, Robert | 0 | 0 |
| Tang, Kevin | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| TANG KEVIN C | 2,443,181 | $0.88 |
| PRENTKI RONALD J | 63,095 | $0.00 |
| PRENTKI RONALD J | 22,556 | $0.90 |
| TURNBULL GREGORY H | 70,000 | $0.00 |
| ROSENBLATT TOBY | 70,000 | $0.00 |
| ZERBE ROBERT L | 70,000 | $0.00 |
| GODDARD PAUL | 70,000 | $0.00 |
| TANG KEVIN C | 175,000 | $0.42 |
| TANG KEVIN C | 415,300 | $0.48 |
| TANG KEVIN C | 66,000 | $0.50 |
| TANG KEVIN C | 775,032 | $0.48 |
| ROSENBLATT TOBY | 40,000 | $0.51 |
| ROSENBLATT TOBY | 6,881 | $0.51 |
| TANG KEVIN C | 336,300 | $0.61 |
| TANG KEVIN C | 870,000 | $0.74 |
| TANG KEVIN C | 650,000 | $0.97 |
| PRENTKI RONALD J | 1,200 | $1.42 |
| PRENTKI RONALD J | 660 | $1.43 |
| PRENTKI RONALD J | 5,000 | $1.47 |
| RIEPENHAUSEN PETER | 9,000 | $0.01 |
| ROSENBLATT TOBY | 9,000 | $0.01 |
| ZERBE ROBERT L | 9,000 | $0.01 |
| GODDARD PAUL | 9,000 | $0.01 |
| TURNBULL GREGORY H | 9,000 | $0.01 |
| TAYLOR ARTHUR T | 9,000 | $0.01 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
